MFA
HZNP

McClarren Financial Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

McClarren Financial Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed – – 431
2023
Q3 		$0 Hold
3
– – ﹤0.01% 418
2023
Q2 		$0 Hold
3
– – ﹤0.01% 487
2023
Q1 		$0 Hold
3
– – ﹤0.01% 482
2022
Q4 		$0 Buy
+3
New +$249 ﹤0.01% 492

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

McClarren Financial Advisors's HZNP Position: Q4 2023 in Review

McClarren Financial Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 3 shares.

McClarren Financial Advisors first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $0 in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • McClarren Financial Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • McClarren Financial Advisors sold 3 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023.
  • McClarren Financial Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • McClarren Financial Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $0 in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on McClarren Financial Advisors's 13F filing for Q4 2023, filed 2 Feb 2024.